Ingenuity Systems Announces Licensing Agreement With Boehringer Ingelheim

IPA will be incorporated into Boehringer Ingelheim’s global research practices

Redwood City, CA April 18, 2006 – Ingenuity Systems today announced that they have entered into an agreement with Boehringer Ingelheim for global access to IPA software.

“Boehringer Ingelheim’s research teams will now have broad access to IPA globally at all sites,” stated Peter DiLaura, Vice President, Sales and Customer Support. “By integrating IPA into their workflows, researchers will shorten the time between data generation and biological interpretation.  This value comes from the ability to understand biology at multiple levels – molecular interactions, association with cellular phenotypes, and understanding disease processes.”

IPA is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research.  IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.

IPA is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at

About Ingenuity Systems®

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan.